June Hwu

Array ( [id] => 15741005 [patent_doc_number] => 20200109390 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-09 [patent_title] => COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS [patent_app_type] => utility [patent_app_number] => 16/608257 [patent_app_country] => US [patent_app_date] => 2018-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13009 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16608257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18201197 [patent_doc_number] => 11583568 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-21 [patent_title] => Methods for administering angiotensin II [patent_app_type] => utility [patent_app_number] => 16/604851 [patent_app_country] => US [patent_app_date] => 2018-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 13352 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762413 [patent_doc_number] => 20210107994 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => MEDICINAL COMPOSITION USABLE FOR PREVENTING AND/OR TREATING BLOOD COAGULATION FACTOR IX ABNORMALITY, COMPRISING MULTISPECIFIC ANTIGEN BINDING MOLECULE REPLACING FUNCTION OF BLOOD COAGULATION FACTOR VIII [patent_app_type] => utility [patent_app_number] => 16/496089 [patent_app_country] => US [patent_app_date] => 2018-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12326 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19013238 [patent_doc_number] => 11920156 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-05 [patent_title] => Engineered natural killer (NK) cells and compositions and methods thereof [patent_app_type] => utility [patent_app_number] => 16/484813 [patent_app_country] => US [patent_app_date] => 2018-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 21817 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292275 [patent_doc_number] => 20210388114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => Procoagulant Antibodies [patent_app_type] => utility [patent_app_number] => 16/481108 [patent_app_country] => US [patent_app_date] => 2018-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38758 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16481108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209899 [patent_doc_number] => 20190367636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => NOVEL STABLE FORMULATION FOR FXIA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/478029 [patent_app_country] => US [patent_app_date] => 2018-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7526 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16478029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16190852 [patent_doc_number] => 20200231701 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => METHODS OF TREATMENT WITH ANTI-FACTOR XI/XIA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/472641 [patent_app_country] => US [patent_app_date] => 2017-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48218 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16472641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15264831 [patent_doc_number] => 20190381149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => METHODS OF TREATING HEMOPHILIC ARTHROPATHY USING CHIMERIC CLOTTING FACTORS [patent_app_type] => utility [patent_app_number] => 16/463748 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36715 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16463748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082139 [patent_doc_number] => 20210277145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INCREASING ENDOGENOUS PROTEIN LEVEL [patent_app_type] => utility [patent_app_number] => 16/461634 [patent_app_country] => US [patent_app_date] => 2017-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16461634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060131 [patent_doc_number] => 11104718 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Red blood cell targeted factor VIII and method of using the same [patent_app_type] => utility [patent_app_number] => 16/349794 [patent_app_country] => US [patent_app_date] => 2017-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 28837 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16349794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527273 [patent_doc_number] => 20200055942 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => TREATMENT REGIMENS [patent_app_type] => utility [patent_app_number] => 16/346896 [patent_app_country] => US [patent_app_date] => 2017-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16176938 [patent_doc_number] => 20200223906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => ANTI-RESPIRATORY SYNCYTIAL VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE [patent_app_type] => utility [patent_app_number] => 16/343311 [patent_app_country] => US [patent_app_date] => 2017-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48286 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 562 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16343311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012831 [patent_doc_number] => 20200181258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => MODIFIED ANTIBODY CONSTANT REGION [patent_app_type] => utility [patent_app_number] => 16/342671 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16342671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17393398 [patent_doc_number] => 11242400 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => CD123 binding proteins and related compositions and methods [patent_app_type] => utility [patent_app_number] => 16/335561 [patent_app_country] => US [patent_app_date] => 2017-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 35 [patent_no_of_words] => 46844 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715687 [patent_doc_number] => 20190248907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => ANTI-C-MET ANTIBODIES AND ANTIBODY DRUG CONJUGATES THEREOF FOR EFFICIENT TUMOR INHIBITION [patent_app_type] => utility [patent_app_number] => 16/333436 [patent_app_country] => US [patent_app_date] => 2017-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17281709 [patent_doc_number] => 11198730 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-14 [patent_title] => Anti-LAG-3 antibody [patent_app_type] => utility [patent_app_number] => 16/325150 [patent_app_country] => US [patent_app_date] => 2017-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 12625 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16325150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17185226 [patent_doc_number] => 20210332111 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => ANTIBODIES TO ZIKA VIRUS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/320872 [patent_app_country] => US [patent_app_date] => 2017-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16320872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14649387 [patent_doc_number] => 20190231822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => METHODS OF REDUCING CHRONIC GRAFT-VERSUS-HOST DISEASE [patent_app_type] => utility [patent_app_number] => 16/317985 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15895433 [patent_doc_number] => 20200147235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/308774 [patent_app_country] => US [patent_app_date] => 2017-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 141740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17044964 [patent_doc_number] => 11098132 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-24 [patent_title] => Anti-factor IX Padua antibodies [patent_app_type] => utility [patent_app_number] => 16/301962 [patent_app_country] => US [patent_app_date] => 2017-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 25016 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16301962 [rel_patent_id] =>[rel_patent_doc_number] =>)